GeneLeap Presents New Preclinical Data for Hydrogel Encapsulated TLR9 Agonist at AACR 2021 |
| April 14, 2021 | April 2021 Bond Updates |
|
BOSTON, April 14, 2021 /PRNewswire/ -- GeneLeap Bio., a subsidiary of Luye Life Sciences specializing in the development of nucleic acid therapeutics, presented an ePoster entitled 'Hydrogel encapsulated TLR9 agonists show sustained tumor growth inhibition and prolong survival of CT26... |
| View more at: https://www.prnewswire.com:443/news-releases/geneleap-presents-new-preclinical-data-for-hydrogel-encapsulated-tlr9-agonist-at-aacr-2021-301268488.html |
| Related News |
|